CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE

心力衰竭的慢性 β 受体阻滞剂治疗

• 批准号: 7376447
• 负责人: E MICHAEL GILBERT
• 金额: $ 6.34万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376447
• 关键词: antihypertensive agents; beta antiadrenergic agent; blood pressure; heart failure; hemodynamics; reduction

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic beta-blocker treatment in heart failure is associated with increases in systolic function, improvement in hemodynamics, reversal of pathologic remodeling , improvement of symptoms, a reduction in hospitalization and a reduction in mortality. Chronic beta-blocker treatment in heart failure is associated with increases in systolic function, improvement in hemodynamics, reversal of pathologic remodeling, improvement of symptoms, a reduction in hospitalization and a reduction in mortality. The clinical evidence for the long-term benefit of beta-blocker therapy is so strong that it is now recommended therapy in all patients with class II or III heart failure symptoms who do not have specific contraindications. This study will investigate whether tolerance to the alpha 1-adrenoceptor blocking effects of carvedilol develops with chronic carvedilol therapy. We will measure the blood pressure and heart rate response to phenylephrine (a pure alpha 1-agonist) infusions in 17 subjects with heart failure. These measurements will be made prior to the initiation of carvedilol therapy, during the uptitration of carvedilol, and after 6 months of continuous carvedilol therapy. The dose of phenylephrine required to increase systolic blood pressure by 20 mm Hg (PS20) and the dose of phenylephrine required to increase diastolic blood pressure by 20 mm Hg (PD20) will be measured. Dose ratios at these doses will be calculated and compared. Prior to enrollment, a blood sample will be obtained to analyze alpha 1-adrenoceptor polymorphisms that could affect the individual's response to phenylephrine.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。慢性β受体阻滞剂治疗心力衰竭与收缩功能的增加，血液动力学改善，病理重塑的逆转，症状改善，住院下降和死亡率降低有关。 慢性β受体阻滞剂治疗心力衰竭与收缩功能的增加，血液动力学改善，病理重塑的逆转，症状改善，住院下降和死亡率降低有关。 β受体阻滞剂治疗的长期益处的临床证据是如此之强，以至于所有没有特定禁忌症的II或III类心力衰竭症状的患者现在建议对治疗进行治疗。 这项研究将研究卡维迪尔慢性卡维迪尔治疗的卡维地醇对α1-肾上腺素受体阻断作用的耐受性。我们将在17名患有心力衰竭的受试者中测量对苯肾上腺素（纯α1激动剂）输注的血压和心率反应。这些测量值将在启动卡维醇治疗，在卡维地洛的膨胀过程中以及在连续6个月的连续卡维丝治疗后进行。将测量将收缩压增加20 mM Hg（PS20）所需的苯肾上腺素剂量，并测量将舒张压增加20 mM Hg（PD20）所需的苯肾上腺素剂量。这些剂量的剂量比将被计算并比较。在入学之前，将获得血液样本，以分析可能影响个人对苯肾上腺素的反应的α-肾上腺素受体多态性。